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Background:  Plastic bronchitis (PB) is a potentially life-threatening disorder found in patients after total cavopulmonary connection 
(TCPC). Although lymphatic abnormalities have been postulated to play a role in the disease process, to date, the etiology and 
pathophysiology of this complication remains incompletely understood. Here we report on the etiology of plastic bronchitis as demonstrated 
by MR lymphangiography and a new potential treatment option for these patients.
methods:  This is a retrospective case series of the 7 patients with TCPC and PB in our institution that underwent T2 non-contrast 
lymphatic mapping, dynamic contrast MR lymphangiography (DCMRL), and selective lymphatic duct embolization (SLDE) procedures.
results:  All 7 (100%) of the patients were after TCPC. By MR lymphangiography all 7 (100%) patients had dilated peribronchial lymphatic 
networks supplied by retrograde lymphatic flow from the TD. This was confirmed by conventional lymphangiography. In four of the patients 
(57%) there was resolution of casting within 1 week of the procedure without recurrence, 2 of the patients had one additional casting 
episode 1 month post procedure, and 1 patient had an additional cast 2 months post procedure in the setting of a severe viral respiratory 
illness. All of the 7 patients (100%) are currently cast free. One of the patient developed PB and chylothorax 4 days after the TCPC 
operation and was headed for TCPC takedown. After SLDE, his effusions and PB resolved and he was discharged home after 2 weeks. 
Median follow-up in this cohort is 3.8 mo with range 2-14 mo. There were no significant complications from the procedure. The most 
common complication has been non-specific transient abdominal and chest pain shortly after the procedure.
Conclusion:  The hallmark finding on MRI in patients with PB are the presence of peribronchial dilated lymphatic networks supplied by 
retrograde lymphatic flow originating from the TD. This leads to continuous spillage of protein into the airway with accretion of material into 
a bronchial cast. SLDE of these networks is feasible and potentially safe. The procedure can result in resolution of PB symptoms and is a 
new possible treatment option for these patients.
